AOC3 and metabolic dysfunction-associated steatohepatitis: BI 1467335 was also being investigated in non-alcoholic steatohepatitis (NASH) [97]; the Phase 2a study met pre-specified targets for inhibiting plasma AOC3 activity compared with placebo and clinically relevant changes in NASH biomarkers [98].